|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
A myc tag can be used in many different assays that require recognition by an antibody. If there is no antibody against the studied protein, adding a myc-tag allows one to follow the protein with an antibody against the Myc epitope. Examples are cellular localization studies by immunofluorescence or detection by Western blotting.
The peptide sequence of the myc-tag is: N-EQKLISEEDL-C (1202 Da). It can be fused to the C-terminus and the N-terminus of a protein. It is advisable not to fuse the tag directly behind the signal peptide of a secretory protein, since it can interfere with translocation into the secretory pathway.
|Rhesus IGFBP4 ORF mammalian expression plasmid, C-GFPSpark tag||CG90080-ACG|
|Rhesus IGFBP4 ORF mammalian expression plasmid, C-OFPSpark / RFP tag||CG90080-ACR|
|Rhesus IGFBP4 ORF mammalian expression plasmid, C-Flag tag||CG90080-CF|
|Rhesus IGFBP4 ORF mammalian expression plasmid, C-His tag||CG90080-CH|
|Rhesus IGFBP4 ORF mammalian expression plasmid, C-Myc tag||CG90080-CM|
|Rhesus IGFBP4 ORF mammalian expression plasmid, C-HA tag||CG90080-CY|
|Rhesus IGFBP4 Gene cDNA clone plasmid||CG90080-G|
|Rhesus IGFBP4 ORF mammalian expression plasmid, N-Flag tag||CG90080-NF|
|Rhesus IGFBP4 ORF mammalian expression plasmid, N-His tag||CG90080-NH|
|Rhesus IGFBP4 ORF mammalian expression plasmid, N-Myc tag||CG90080-NM|
|Rhesus IGFBP4 ORF mammalian expression plasmid, N-HA tag||CG90080-NY|
|Rhesus IGFBP4 natural ORF mammalian expression plasmid||CG90080-UT|
|Learn more about expression Vectors|
Insulin-like growth factor binding protein 4 (IGFBP-4) is a 24-kDa protein that binds insulin-like growth factor 1 (IGF-1) and IGF-2 with high affinity and inhibits IGF action in vitro. The Insulin-like growth factor-binding protein also known as IGFBP serves as a carrier protein for Insulin-like growth factor 1. IGFBPs are clearly distinct but are sharing regions with strong homology. All members of the IGFBP family bind IGF-I and IGF-II with about equal affinity. Insulin-like growth factor (IGF) binding proteins (IGFBPs) have been shown to either inhibit or enhance the action of IGF, or act in an IGF-independent manner in the prostate. IGF-binding protein-4 (IGFBP-4) inhibits IGF-I action in vitro and is the most abundant IGFBP in the rodent arterial wall. Expression of IGFBP-4 mRNA in nontransgenic littermates was maximal in liver and kidney. IGFBP-4 is a functional antagonist of IGF-I action on SMC. There is mounting evidence that the structure of the IGFBP proteins plays a key role in the regulation of IGF bioavailability, by modulating its molecular size, capillary membrane permeability, target tissue specificity, cell membrane adherence and IGF affinity.